[{"id":"42863ddc-f4db-4ccc-bee0-c2c0b6477bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03300817","created_at":"2024-01-03T14:17:29.800Z","updated_at":"2024-07-02T16:34:26.572Z","phase":"Phase 1","brief_title":"MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer","source_id_and_acronym":"NCT03300817","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • MUC1 • CRP","pipe":"","alterations":" ","tags":["IL6 • MUC1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/23/2021","primary_completion_date":" 09/23/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"1debf4f5-fe7e-4f3a-9c9e-51c260b4e71b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411497","created_at":"2024-01-03T16:18:11.493Z","updated_at":"2024-07-02T16:35:07.262Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05411497","lead_sponsor":"Mayo Clinic","biomarkers":" MUC1","pipe":" | ","alterations":" MUC1 expression","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-04-26"},{"id":"3179b0f4-ea2a-4800-a780-ec771c8348bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06218303","created_at":"2024-01-23T18:20:49.964Z","updated_at":"2024-07-02T16:35:15.510Z","phase":"Phase 1","brief_title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","source_id_and_acronym":"NCT06218303","lead_sponsor":"Finn, Olivera, PhD","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/07/2024","start_date":" 02/07/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-03-08"},{"id":"590e53d1-c310-49ee-97e0-d23db9389e60","acronym":"16-C-0048","url":"https://clinicaltrials.gov/study/NCT02649855","created_at":"2023-07-21T15:09:43.248Z","updated_at":"2024-07-02T16:35:31.054Z","phase":"Phase 2","brief_title":"Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer","source_id_and_acronym":"NCT02649855 - 16-C-0048","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • MUC1 • TNFA • CEACAM5 • CD4 • IL2 • LAMP1","pipe":"","alterations":" ","tags":["CD8 • IFNG • MUC1 • TNFA • CEACAM5 • CD4 • IL2 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • ProstVac (rilimogene galvacirepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/19/2016","start_date":" 01/19/2016","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 08/08/2024","study_completion_date":" 08/08/2024","last_update_posted":"2023-10-31"},{"id":"3f5c0ab2-0f8a-478a-9e82-1e103a467f1f","acronym":"MINDGAP","url":"https://clinicaltrials.gov/study/NCT04727593","created_at":"2021-01-27T13:54:10.090Z","updated_at":"2024-07-02T16:35:38.121Z","phase":"","brief_title":"The Modulatory Role of Internet MBCT on Extracellular Vesicles and Distress in Cancer Patients - Study Protocol","source_id_and_acronym":"NCT04727593 - MINDGAP","lead_sponsor":"Instituto Portugues de Oncologia, Francisco Gentil, Porto","biomarkers":" IL6 • MUC1 • CEACAM5 • CXCL8 • IL10","pipe":"","alterations":" ","tags":["IL6 • MUC1 • CEACAM5 • CXCL8 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 09/03/2021","start_date":" 09/03/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-09-04"},{"id":"d9fd809b-eb43-4044-9ecf-63c36ff9e599","acronym":"","url":"https://clinicaltrials.gov/study/NCT04695847","created_at":"2021-01-19T20:49:32.993Z","updated_at":"2025-02-25T16:10:59.679Z","phase":"Phase 1","brief_title":"M1231 in Participants With Solid Tumors","source_id_and_acronym":"NCT04695847","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" EGFR • MSI • MUC1","pipe":" | ","alterations":" MSI-H/dMMR • EGFR expression","tags":["EGFR • MSI • MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M1231"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 06/23/2023","study_completion_date":" 06/23/2023","last_update_posted":"2023-07-07"},{"id":"c6f9cbc2-76fa-4211-9fb0-5b14aa0568d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04020575","created_at":"2021-01-18T19:44:34.590Z","updated_at":"2024-07-02T16:35:45.435Z","phase":"Phase 1","brief_title":"Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)","source_id_and_acronym":"NCT04020575","lead_sponsor":"Minerva Biotechnologies Corporation","biomarkers":" HER-2 • PGR • MUC1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative","tags":["HER-2 • PGR • MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huMNC2-CAR22 • huMNC2-CAR44 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/15/2035","study_completion_date":" 01/15/2035","last_update_posted":"2023-06-16"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"921dec47-a56c-4a58-a252-f8c3cb8a0f87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05278078","created_at":"2022-03-14T13:53:57.954Z","updated_at":"2024-07-02T16:36:15.459Z","phase":"","brief_title":"Slimming Myokines, Cancers,Nutritional and Psychology Support","source_id_and_acronym":"NCT05278078","lead_sponsor":"T.C. ORDU ÜNİVERSİTESİ","biomarkers":" MUC1 • CEACAM5 • CA 19-9 • CRP","pipe":"","alterations":" ","tags":["MUC1 • CEACAM5 • CA 19-9 • CRP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2022-03-14"},{"id":"b8578e8d-7833-452c-bdde-46cc07292ef8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05046366","created_at":"2021-09-16T14:52:58.365Z","updated_at":"2024-07-02T16:36:20.666Z","phase":"","brief_title":"Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.","source_id_and_acronym":"NCT05046366","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" MUC1 • CEACAM5 • B2M • KRT19 • CRP","pipe":"","alterations":" ","tags":["MUC1 • CEACAM5 • B2M • KRT19 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-11-16"},{"id":"eb6b8c58-147e-4fe6-a399-4af138a368f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00706615","created_at":"2021-01-18T02:38:34.418Z","updated_at":"2024-07-02T16:36:42.522Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer","source_id_and_acronym":"NCT00706615","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" MUC1","pipe":" | ","alterations":" MUC1 elevation","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 elevation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 04/01/2009","primary_completion_date":" 04/01/2009","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-31"},{"id":"ba651488-3e2a-4754-86e6-1d71d3948062","acronym":"Argo","url":"https://clinicaltrials.gov/study/NCT02613208","created_at":"2021-01-18T12:41:42.382Z","updated_at":"2024-07-02T16:36:49.906Z","phase":"","brief_title":"A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer","source_id_and_acronym":"NCT02613208 - Argo","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • PGR • MUC1 • CEACAM5","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR • MUC1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 12/09/2015","start_date":" 12/09/2015","primary_txt":" Primary completion: 12/03/2018","primary_completion_date":" 12/03/2018","study_txt":" Completion: 12/03/2018","study_completion_date":" 12/03/2018","last_update_posted":"2020-02-17"},{"id":"0461c7a7-21e2-4e81-904b-eaaa59fe9275","acronym":"","url":"https://clinicaltrials.gov/study/NCT00773097","created_at":"2021-01-18T02:55:17.301Z","updated_at":"2024-07-02T16:37:04.205Z","phase":"Phase 2","brief_title":"Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma","source_id_and_acronym":"NCT00773097","lead_sponsor":"Robert Schoen","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 10/01/2011","primary_completion_date":" 10/01/2011","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2019-01-07"},{"id":"a3660b0c-6ed3-4249-9b3d-fdf23e01573d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00640861","created_at":"2021-01-18T02:23:05.773Z","updated_at":"2024-07-02T16:37:05.719Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer","source_id_and_acronym":"NCT00640861","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • CD8 • IFNG • MUC1 • CD4 • IL5","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • PGR expression • HLA-A2 positive","tags":["HER-2 • CD8 • IFNG • MUC1 • CD4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • PGR expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2/neu peptide vaccine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 08/28/2008","start_date":" 08/28/2008","primary_txt":" Primary completion: 04/21/2015","primary_completion_date":" 04/21/2015","study_txt":" Completion: 04/21/2015","study_completion_date":" 04/21/2015","last_update_posted":"2018-10-31"},{"id":"bd47dd42-9e42-4495-884c-94076f8c36c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02270372","created_at":"2021-01-18T10:40:37.901Z","updated_at":"2024-07-02T16:37:10.668Z","phase":"Phase 1b","brief_title":"Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer","source_id_and_acronym":"NCT02270372","lead_sponsor":"Cascadian Therapeutics Inc.","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlilumab (CDX 1127) • ONT-10"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2018-05-17"},{"id":"f7a6174e-7fc7-43b8-86df-9aff3711091d","acronym":"EMR 63325-015","url":"https://clinicaltrials.gov/study/NCT01496131","created_at":"2021-01-18T06:16:08.326Z","updated_at":"2024-07-02T16:37:13.158Z","phase":"Phase 2","brief_title":"Tecemotide (L-BLP25) in Prostate Cancer","source_id_and_acronym":"NCT01496131 - EMR 63325-015","lead_sponsor":"EMD Serono","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • goserelin acetate • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 10/24/2011","start_date":" 10/24/2011","primary_txt":" Primary completion: 11/25/2016","primary_completion_date":" 11/25/2016","study_txt":" Completion: 11/25/2016","study_completion_date":" 11/25/2016","last_update_posted":"2018-03-09"},{"id":"7c6bfff4-5011-444a-90d9-1ef097eadebd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01462513","created_at":"2021-01-18T06:05:01.468Z","updated_at":"2024-07-02T16:37:13.981Z","phase":"Phase 2","brief_title":"L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases","source_id_and_acronym":"NCT01462513","lead_sponsor":"Prof. Dr. Carl Schimanski","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stimuvax (tecemotide)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 12/31/2017","primary_completion_date":" 12/31/2017","study_txt":" Completion: 01/31/2018","study_completion_date":" 01/31/2018","last_update_posted":"2018-02-13"},{"id":"7fe18166-07b7-46bf-bb2e-c3e9821677cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00410813","created_at":"2021-01-18T01:26:28.381Z","updated_at":"2024-07-02T16:37:20.416Z","phase":"Phase 2","brief_title":"S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone","source_id_and_acronym":"NCT00410813","lead_sponsor":"Southwest Oncology Group","biomarkers":" HER-2 • ER • MUC1 • MUC16","pipe":" | ","alterations":" HER-2 positive • PGR positive","tags":["HER-2 • ER • MUC1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2017-07-02"},{"id":"d5f1c7b7-571c-4dca-be3f-7ecc50e0892d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03179007","created_at":"2021-01-18T15:40:32.243Z","updated_at":"2024-07-02T16:37:21.339Z","phase":"Phase 1/2","brief_title":"CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT03179007","lead_sponsor":"Shanghai Cell Therapy Research Institute","biomarkers":" MUC1 • CTLA4","pipe":" | ","alterations":" MUC1 expression","tags":["MUC1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 01/20/2019","primary_completion_date":" 01/20/2019","study_txt":" Completion: 04/20/2019","study_completion_date":" 04/20/2019","last_update_posted":"2017-06-07"},{"id":"50680306-c8c0-4e02-9bf0-71ac36cdd8cd","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT01507103","created_at":"2021-01-18T06:19:59.567Z","updated_at":"2025-02-25T14:49:33.046Z","phase":"Phase 2","brief_title":"Tecemotide (L-BLP25) in Rectal Cancer","source_id_and_acronym":"NCT01507103 - SPRINT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" MSI • CD8 • IFNG • MLH1 • MSH6 • MUC1 • MSH2 • CEACAM5 • ISG20","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • CD8 • IFNG • MLH1 • MSH6 • MUC1 • MSH2 • CEACAM5 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2017-01-13"}]